Compare BESS & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BESS | DARE |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 16.6M |
| IPO Year | 2022 | 2014 |
| Metric | BESS | DARE |
|---|---|---|
| Price | $2.91 | $0.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.50 | $6.33 |
| AVG Volume (30 Days) | ★ 268.8K | 115.8K |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $168,880.00 | ★ $2,807,885.00 |
| Revenue This Year | N/A | $116.54 |
| Revenue Next Year | $206.88 | $201.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $0.61 |
| 52 Week High | $6.45 | $3.78 |
| Indicator | BESS | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 40.09 |
| Support Level | $2.75 | $0.62 |
| Resistance Level | $3.17 | $0.74 |
| Average True Range (ATR) | 0.45 | 0.04 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 42.81 | 26.98 |
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.